McKenney J M, Kinosian B
Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
Am J Manag Care. 1998 Jan;4(1):65-74.
Coronary heart disease (CHD) has high prevalence in the United States and is associated with significant mortality as well as costs to society. Hyperlipidemia is a major and common modifiable risk factor for CHD. In clinical trials, cholesterol-lowering strategies have a dramatic impact on CHD risk, cardiovascular events, and mortality. Cost-effectiveness data have established that clinical and economic benefits are gained by instituting early and aggressive lipid-lowering therapy. We present new evidence for the clinical benefits and cost effectiveness of aggressive lipid-lowering therapy as primary or secondary prevention of CHD and describe strategies that managed care organizations can take to benefit from a lipid management program.
冠心病（CHD）在美国具有很高的患病率，与显著的死亡率以及社会成本相关。高脂血症是冠心病的一个主要且常见的可改变风险因素。在临床试验中，降低胆固醇的策略对冠心病风险、心血管事件及死亡率有显著影响。成本效益数据表明，通过实施早期积极的降脂治疗可获得临床和经济效益。我们提供了新的证据，证明积极降脂治疗作为冠心病一级或二级预防的临床益处和成本效益，并描述了管理式医疗组织可采取的从血脂管理计划中获益的策略。
